contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


interim-report-fourth-quarter-2024-october-1-december-31-kancera-ab-publ-orgno-556806-8851

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Novakand Pharma is a pharmaceutical company. The company develops drugs that counteract damage caused by acute and chronic inflammation. The products are mainly developed to counteract hyperinflammation in various disease states and thereby protect vital organs, for example in connection with heart attacks and severe viral infections. Novakand Pharma is planning two clinical phase II studies, in COVID-19 and in heart patients. The company conducts research and development at Karolinska Institutet Science Park in Stockholm.

Novakand Pharma

The period in brief – financial summary for the fourth quarter 2024Net sales amounted to SEK 0 million (SEK 0 million).R&D expenses amounted to SEK 8,5 million (SEK 17,1 million).Operating loss...

<div class="mfn-body">The period in brief – financial summary for the fourth quarter 2024<ul><li>Net sales amounted to SEK 0 million (SEK 0 million).</li><li>R&amp;D expenses amounted to SEK 8,5 million (SEK 17,1 million).</li><li>Operating loss for the quarter amounted to SEK –9,9 million (SEK -19,0 million).</li><li>Loss after financial items for the quarter amounted to SEK –9,6 million (SEK -18,5 million).</li><li>Basic and diluted earnings per share for the quarter amounted to SEK –0,08 (SEK -0,23).</li><li>Cash flow from operating activities for the quarter amounted to SEK –11,6 million (SEK -12,5 million).</li><li>Equity on December 31, 2024 amounted to SEK 62,3 million (SEK 47,7 million) or SEK 0,51 (SEK 0,58) per share.</li><li>The equity/assets ratio on December 31, 2024 was 94 percent (73 percent).</li><li>Cash and cash equivalents on December 31, 2024 amounted to SEK 46,4 million (SEK 45,7 million).</li></ul>Financial summary for the full period January 1-December 31, 2024<ul><li>Net sales amounted to SEK 0 million (SEK 0 million).</li><li>R&amp;D expenses amounted to SEK 40,0 million (SEK 58,0 million).</li><li>Operating loss for the quarter amounted to SEK –46,2 million (SEK -65,0 million).</li><li>Loss after financial items for the quarter amounted to SEK –44,6 million (SEK -64,9 million).</li><li>Basic and diluted earnings per share for the quarter amounted to SEK –0,39 (SEK -0,81).</li><li>Cash flow from operating activities amounted to SEK –58,5 million (SEK -55,7 million).</li><li>Equity on December 31, 2024 amounted to SEK 62,3 million (SEK 47,7 million) or SEK 0,51 (SEK 0,58) per share.</li><li>The equity/assets ratio on December 31, 2024 was 94 percent (73 percent).</li><li>Cash and cash equivalents on December 31, 2024 amounted to SEK 46,4 million (SEK 45,7 million)..</li></ul>Significant events during the fourth quarter 2024<ul><li>Kancera Kancera announced that the company is focusing its business on the field of cardiovascular diseases.</li><li>Kancera reported that the patient recruitment in the ongoing clinical study in ovarian cancer (KANDOVA) is stopped and that top-line results are expected to be presented in the fourth quarter 2025.</li><li>Kancera reported that Robert Edfors is appointed as Chief Medical Officer..</li></ul>Significant events after the end of the period<ul><li>No significant events have been reported after the period.</li></ul>About Kancera AB (publ) Kancera is developing a new class of anti-inflammatory drugs in the field of cardiovascular diseases through its candidate drugs KAND567 and KAND145. Kancera’s anti-inflammatory candidate drugs are targeting the fractalkine axis, which controls specific immune cells with high precision. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser.For further information Please refer the presentation of the 2024 Q4 Interim Report, available on Kancera’s website: <a rel="noopener" href="http://www.kancera.com/en/investor-relations/presentations/">www.kancera.com/en/investor-relations/presentations/</a>or contact: <a rel="noopener" href="mailto:ir@kancera.com">ir@kancera.com</a> or phone: +46 (0)8-5012 60 80</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/daaec9d2-5bfd-4efc-a2d3-a9ffca261534/kancera-interim-report-2024-q4.pdf" class="mfn-primary">Kancera Interim Report 2024 Q4</a></div>

Interim Report Fourth Quarter 2024, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851